Showing 1 - 5 results of 5 for search 'Edmund Capparelli', query time: 0.04s Refine Results
  1. 1
    Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis.

    Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. by Rosa M Andrade, Juan D Chaparro, Edmund Capparelli, Sharon L Reed

    Published 2014-01-01
    Get full text
    Article
  2. 2
    Meropenem pharmacokinetics during relapsing peritonitis due to ESBL‐producing Enterobacteriaciae in a liver transplant recipient

    Meropenem pharmacokinetics during relapsing peritonitis due to ESBL‐producing Enterobacteriaciae in a liver transplant recipient by Kensuke Shoji, Jumpei Saito, Yusuke Oho, Shotaro Matsumoto, Satoshi Aoki, Akinari Fukuda, Seisuke Sakamoto, Mureo Kasahara, Edmund Capparelli, Isao Miyairi

    Published 2019-11-01
    Get full text
    Article
  3. 3
    Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

    Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol... by Nigel Garrett, Sharana Mahomed, Edmund Capparelli, Cheryl Baxter, Tanuja Gengiah, Derseree Archary, Penny Moore, Natasha Samsunder, Dan H Barouch, John Mascola, Julie Ledgerwood, Lynn Morris, Salim Abdool Karim, Catherine Hankins, Quarraisha A Karim, Nonhlanhla Y Zuma, Carolyn Williamson, Patricia E Fast, Bruno Pozzetto, Kevin Carlton, Nicole Doria-Rose

    Published 2020-11-01
    Get full text
    Article
  4. 4
    Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial

    Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAP... by Nigel Garrett, Farzana Osman, Sharana Mahomed, Edmund Capparelli, Nonhlanhla Yende Zuma, Derseree Archary, Penny Moore, Natasha Samsunder, Lynn Morris, Salim Abdool Karim, Catherine Hankins, Carolyn Williamson, Bruno Pozzetto, Kevin Carlton, Richard A Koup, Quarraisha Abdool Karim, Leila Mansoor, Tanuja Narayansamy Gengiah, Ishana Harkoo, Precious Radebe, Izukanji T Sikazwe, Disebo Potloane, Nqobile Myeni, Nicole Doria Rose, Lucio Gama, Sandeep Narpala, Leonid Serebryannyy

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

    Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. by Martin R Gaudinski, Emily E Coates, Katherine V Houser, Grace L Chen, Galina Yamshchikov, Jamie G Saunders, LaSonji A Holman, Ingelise Gordon, Sarah Plummer, Cynthia S Hendel, Michelle Conan-Cibotti, Margarita Gomez Lorenzo, Sandra Sitar, Kevin Carlton, Carolyn Laurencot, Robert T Bailer, Sandeep Narpala, Adrian B McDermott, Aryan M Namboodiri, Janardan P Pandey, Richard M Schwartz, Zonghui Hu, Richard A Koup, Edmund Capparelli, Barney S Graham, John R Mascola, Julie E Ledgerwood, VRC 606 Study Team

    Published 2018-01-01
    Get full text
    Article

Search Tools: